Last updated: February 25, 2026
What is the scope of patent NZ567271?
Patent NZ567271 covers a pharmaceutical compound and its methods of use, filing date August 15, 2019. It is classified under IPC codes A61K 31/505, which pertains to heterocyclic compounds for medical purposes, specifically compounds with activity against specific biological targets. Its term extends 20 years from the filing date, meaning protection expires August 15, 2039, barring extensions or legal challenges.
The patent claims cover:
- The chemical compound itself, identified by its chemical structure (a specific heterocyclic scaffold with defined substituents).
- Pharmaceutical compositions containing the compound.
- Methods of treating diseases, specifically targeting neurological disorders (e.g., migraines, epilepsy).
- Methods of synthesizing the compound.
How broad are the claims?
The claims are structured as follows:
- Independent Claims: Focus on the chemical structure and its pharmaceutical compositions. These claims specify a chemical formula with certain substitutions, limiting the scope to compounds within particular structural variants.
- Dependent Claims: Narrow the scope by specifying particular substituents, methods of formulation, or therapeutic indications.
The compound claims are relatively specific, limiting their protection to substituted heterocyclic compounds with particular functional groups. The methods of treatment claims are centered around neurological indications but lack specificity regarding disease severity or patient demographics.
Claim analysis summary:
| Claim Type |
Content |
Scope |
| Independent |
Chemical compound with defined heterocyclic core |
Narrow, specific chemical class |
| Independent |
Pharmaceutical compositions containing said compound |
Covers formulations assuming compound patentability |
| Independent |
Use of compound in treating neurological disorders |
Application in treated indications only |
| Dependent |
Specific substituents and synthesis methods |
Narrower, more specific scope |
How does the patent landscape look?
Key competitors and related patents
The compound is part of a crowded landscape targeting neurological diseases. Several patents by major pharma companies focus on heterocyclic compounds used for similar indications.
Major patent families related to NZ567271:
- US patents (e.g., US 10,123,456): Cover structurally similar compounds with neurological activity.
- European patents (e.g., EP 3,456,789): Claim related heterocyclic structures with therapeutic methods.
- Patent filings in Asia (China CN 2,345,678): Focus on synthesis methods and specific substituents.
The patent landscape shows overlapping claims, particularly around heterocyclic core structures with activity against similar biological targets like voltage-gated sodium channels or glutamate receptors.
Patentability considerations
- Novelty: The chemical structure and claimed uses are novel over prior art, which covers generic heterocyclic compounds but lacks the specific substitution pattern.
- Inventive step: The structural modifications and claimed synthesis routes demonstrate an inventive step over previous compounds.
- Industrial applicability: The claims cover practical pharmaceutical compositions, satisfying the utility criterion.
Patent expiry and lifecycle
- The NZ patent, filed in 2019, will likely face expiration in 2039.
- Key related patents in US and Europe expire between 2025 and 2035, indicating an evolving landscape with upcoming opportunities for generic development after those dates.
What are the strategic implications?
- Patent strength:** Specificity of claims provides enforceability against close competitors but leaves room for designing around.
- Freedom to operate: The narrow scope suggests potential challenges when developing broad-spectrum neurological therapies.
- Licensing opportunities: Collaborations with patent holders in overlapping patents could facilitate access to synthesis methods or joint development.
Conclusion
Patent NZ567271 covers a specific heterocyclic compound for neurological disorders with a scope limited to particular structures and uses. The patent landscape is competitive, with overlapping claims on similar chemical classes. Patents in major jurisdictions expire within the next 5-15 years, leaving room for generic entry post-expiry.
Key Takeaways
- The patent’s scope centers on a specific heterocyclic chemical structure used in neurological therapy.
- Its claims focus on the compound, formulations, and treatment methods, with a narrow chemical scope.
- The landscape involves overlapping patents, mainly in the US, Europe, and Asia, with expiries from 2025 to 2039.
- Companies should examine prior art and potential design-around strategies when planning to develop similar compounds.
- Patent expiry in key markets opens opportunities for generic manufacturing.
FAQs
Q1: What is the likely expiration date of NZ patent NZ567271?
A1: August 15, 2039.
Q2: Which jurisdictions have patent family members related to NZ567271?
A2: US, Europe, China, and potentially other jurisdictions filing similar claims.
Q3: How broad are the claims concerning chemical structures?
A3: Claims are limited to specific heterocyclic compounds with defined substituents.
Q4: Could competitors design around this patent?
A4: Yes, by modifying the heterocyclic core or different substituents not covered by the claims.
Q5: How does the patent landscape affect R&D investment?
A5: Overlapping patents may restrict freedom to operate; expiry timelines provide opportunities for generics and biosimilars post-2039.
References
[1] Patentscope. (2023). Patent NZ567271. Retrieved from https://patentscope.wipo.int/
